Cancer Patients
Conditions
Interventions
None listed
Sponsors
Yokohama City University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Only papers in English will be incorporated. Other articles (e.g., non-English papers, short reports, conference abstracts, etc.) will be excluded. Include parallel-group, individually randomized controlled trials (RCTs), but not cluster RCTs or crossover RCTs; trials with more than three arms will also be included if they meet the criteria. Include non-inferiority trials as well as superiority trials. RCTs of any phase will be included, but trials that do not report safety data will be excluded. The main inclusion criteria are. (1) RCTs including angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptors blockers (ARB) arm and control arm in adult malignancies. Controls were classified as placebo or non-placebo. (2) For multi-arm studies, at least one arm must include an ACE inhibitor or ARB group. (3)Trials that demonstrate efficacy results such as cardioprotection, reduction in respiratory distress, or improvement in quality of life.
Exclusion criteria
Exclusion criteria: (1) Systematic review or meta-analysis articles. (2) Retrospective analysis. (3) Single prospective cohort study without a control group. (4) Non-RCT. (5) The republished research literature is excluded unless the research includes new findings related to outcomes listed in inclusion criteria. (6) Studies with no or insufficient safety results at the time of the literature search. (7) Studies published in languages other than English. Two investigators independently screened all titles, abstracts, and full texts for eligibility. Final inclusion will be decided after resolving discrepancies between the two investigators.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is to evaluate ACE inhibitor/ARB treatment in patients being treated for malignancy in relation to reduction in cardiotoxicity, respiratory distress, and improvement in quality of life. | — |
Countries
Japan
Contacts
Public ContactShintaro Minegishi
Yokohama City University Graduate School of Medicine Department of Cardiology
Outcome results
None listed